Differential molecular response of larynx cancer cell lines to combined VPA/CDDP treatment

xlomafota13 shared this article with you from Inoreader Differential molecular response of larynx cancer cell lines to combined VPA/CDDP treatment Via American Journal of Cancer Research Am J Cancer Res. 2021 Jun 15;11(6):2821-2837. eCollection 2021. ABSTRACT Successful treatment of advanced larynx squamous cell carcinoma (LSCC) remains a challenge, mainly due to limited response to chemotherapy and the phenomenon of the drug resistance. Therefore, new chemotherapeutic solutions are needed. The aim of this study was to explore benefit of combined cisplatin (CDDP) and valproic acid (VPA) therapy in patients' derived LSCC cell lines. Cell viability assay was used to establish cellular response to the drug by isobolography followed by RNA sequencing (RNAseq) analysis. Danio rerio were used for in vivo studies. Depending on the cell line, we found that the combinations of drugs resulted in synergistic or antagonistic pharmacological interaction, which was accompanied by significant changes in genes expression profiles. The presented therapeutic scheme efficiently blocked tumor growth in an in vivo mode l, corresponding to the in vitro performed studies. Interestingly the RK5 cell line, upon the combined treatment acquired a molecular profile typically associated with epithelial to mesenchymal transition (EMT). Hence, our studies demonstrates that patient-specific personalized therapy of larynx cancer should be considered and the combination of cisplatin and valproic acid should be explored as a potential therapeutic strategy in the treatment of larynx cancer. PMID:34249430 | PMC:PMC8263637 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.